Sanofi and Regeneron’s Dupixent shows consistent safety profile
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
Read Moreby John Pinching | Sep 5, 2022 | News | 0
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
Read Moreby John Pinching | May 26, 2022 | News | 0
Libtayo has been approved for adults when curative surgery or radiation is not appropriate
Read Moreby Lucy Parsons | Sep 21, 2021 | News | 0
Ronapreve will be targeted at hospitalised patients who have not mounted an antibody response against COVID-19
Read Moreby Lucy Parsons | Sep 20, 2021 | News | 0
Positive data presented at the 2021 ESMO virtual congress
Read Moreby Lucy Parsons | Aug 31, 2021 | News | 0
Sanofi/Regeneron biologic offers alternative to topical steroids
Read Moreby Lucy Parsons | Aug 20, 2021 | News | 0
Regeneron/Roche’s drug found to reduce hospitalisation
Read Moreby Selina McKee | Jun 25, 2021 | News | 0
Libtayo is the first immunotherapy indicated for patients with advanced basal cell carcinoma
Read Moreby Lucy Parsons | Feb 10, 2021 | News | 0
First immunotherapy indicated for certain BCC patients
Read Moreby Selina McKee | Sep 1, 2020 | News | 0
Sanofi and Regeneron do not anticipate carrying out further research on Kevzara in COVID-19
Read Moreby Selina McKee | Jul 7, 2020 | News | 0
This follows a positive review from the Independent Data Monitoring Committee of REGN-COV2 Phase I safety results
Read Moreby Selina McKee | Jul 3, 2020 | News | 0
The drug failed to show any significant benefit in patient requiring mechanical ventilation
Read Moreby Selina McKee | Jun 25, 2020 | News | 0
The ‘landmark’ decision invalidates Regeneron’s patent claims covering its genetically modified mice
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479